Arab Health 2025｜yuwell Medical announces strategic investment and partnership with innogen in the field of Respiratory Health Investing.com

Dubai, UaeWho,, 26. January 2025 / Prnewire/ – on the eve Arab Health ExhibitionYuwell Medical (Tase 🙂 held his own 2025 Global key partner conference in Dubaiand announced a Strategic Investment and Partnership with Inogen (Nasdaq 🙂leading OUR Respiratory health company, emphasizing our joint commitment to improving solutions for medical devices and deeper cooperation.

Speaking on the Yuwell Medical 2025 Global key partner conferenceAlex Wu, President Yuwell Medicala, stated that as a leading company in Chinese Home medical devices industries, Yuwell will rely on internal growth and external merging and acquisition to promote internationalization. The company has updated its new vision for the next five years: to become three leading companies in the global home medicine market in the middle and long term. Among them are three key strategic sector solutions for the treatment of airways, diabetes care and emergency solutions. The company will further strengthen its globalization strategy with three aspects: the expansion of organizational structure, employment of extraordinary foreign talents, innovation in research and development of products and innovation of the supply chain integration.

He further emphasized: “In the process of achieving a new vision, Yuwell will work a hand in hand with global partners to provide users with more competitive products and better health solutions.”

During the Yuwell Medical Conference and the American company Inogen formalized the cooperation with signing a Memorandum on Strategic Investment and Cooperationfurther deepening your partnership in respiratory segment.

As one of the world’s largest oxygen concentrator manufacturers, Yuwell Medical is widely known for its strong Research and Development Opportunities and advanced production capabilities.

Inogen, leading OUR The manufacturer of oxygen concentrator brings great experience in the technology of the oxygen transmission concentrator. Yuwell, through your complete -owned branch of Yuwell (Hong Kong) Holdings Limitedit agreed to invest in approximately $ 27.2 million Inogen, which represents 9.9% of the Inogenic ordinary shares after closing this investment.

Two companies seek to improve the device technology through deepened cooperation. Combining your expertise and brand in their industry segments and geographical fields, Yuwell and Inogen consonant a depth strategic cooperation based on business synergy in four aspects: international distribution operations, licensing trademarks and distribution business, joint research and development, and optimization of the supply chain .

Yuwell Medical and Inogen are excited to build a long -term strategic partnership, ready to use the opportunities that appear in today’s market. Together they aim to increase their international competitiveness and deliver innovative products that improve lives around the world.

Looking forward, Yuwell Medical will remain focused on innovationinitiating progress in medical technology and working with global partners to form a health care future.